Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26967587 | 0.90 | TSHR (0.33) | MEN1ALDH1A1KMT2A | |
| SCHEMBL5561677 | 0.80 | TDP1 (0.35) | MEN1ALDH1A1KMT2ATHRBLMNA | |
| SCHEMBL23860129 | 0.78 | ACHE (0.30) | — | |
| SCHEMBL854693 | 0.77 | THRB (0.44) | THRBLMNA | |
| SCHEMBL25755551 | 0.75 | — | — | |
| SCHEMBL277640 | 0.75 | THRB (0.42) | ALDH1A1THRBLMNA | |
| SCHEMBL11760550 | 0.72 | THRB (0.40) | THRBLMNA | |
| SCHEMBL352734 | 0.72 | — | — | |
| SCHEMBL2090540 | 0.70 | — | — | |
| SCHEMBL26879942 | 0.70 | MEN1 (0.33) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383868-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-11-21 | — | — | US | disclosed |
| EP-4294790-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022178532-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| US-7547679-B2 | Ether linked macrolides useful for the treatment of microbial infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2009-06-16 | — | — | US | disclosed |
| EP-1879903-A1 | ETHER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006120541-A1 | ETHER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258600-A1 | 14- or 15-Membered macrolides substituted at the 4'' position such as 4''-O-[2-(2-{2-[2-(3-Carboxy-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinolin-6-ylamino)-ethoxy]-ethoxy}-ethylamino)-ethyl]-azithromycin 11,12-cyclic carbonate; therapy or prophylaxis of systemic or topical microbial infections | IL17A, IL15, CASP14 | MEN1 2785/4885ALDH1A1 3802/4885KMT2A 3668/4885 |
| US-20240383868-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | MEN1 2085/4885ALDH1A1 2230/4885KMT2A 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.